Research programme: lipid metabolism disorder therapeutics - Lipid Genomics
Latest Information Update: 22 Jul 2016
At a glance
- Originator Lipid Genomics
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action SCARB1 protein modulators; Scavenger receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lipid metabolism disorders